SI2805731T1 - Stabilne formulacije polipeptidov in njihove uporabe - Google Patents
Stabilne formulacije polipeptidov in njihove uporabeInfo
- Publication number
- SI2805731T1 SI2805731T1 SI201031846T SI201031846T SI2805731T1 SI 2805731 T1 SI2805731 T1 SI 2805731T1 SI 201031846 T SI201031846 T SI 201031846T SI 201031846 T SI201031846 T SI 201031846T SI 2805731 T1 SI2805731 T1 SI 2805731T1
- Authority
- SI
- Slovenia
- Prior art keywords
- polypeptides
- stable formulations
- formulations
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27581609P | 2009-09-03 | 2009-09-03 | |
US28450209P | 2009-12-18 | 2009-12-18 | |
EP14171120.0A EP2805731B1 (en) | 2009-09-03 | 2010-09-03 | Stable formulations of polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2805731T1 true SI2805731T1 (sl) | 2019-02-28 |
Family
ID=42797362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201031846T SI2805731T1 (sl) | 2009-09-03 | 2010-09-03 | Stabilne formulacije polipeptidov in njihove uporabe |
Country Status (12)
Country | Link |
---|---|
US (2) | US9884117B2 (sl) |
EP (5) | EP2805731B1 (sl) |
CY (1) | CY1121411T1 (sl) |
DK (2) | DK2473527T3 (sl) |
ES (3) | ES2531083T3 (sl) |
HK (1) | HK1204284A1 (sl) |
HR (1) | HRP20190137T1 (sl) |
LT (1) | LT2805731T (sl) |
PL (2) | PL2473528T3 (sl) |
PT (3) | PT2473527T (sl) |
SI (1) | SI2805731T1 (sl) |
WO (2) | WO2011026945A1 (sl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8629244B2 (en) * | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
AU2009333791B2 (en) | 2008-10-29 | 2013-04-04 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
US10118962B2 (en) | 2008-10-29 | 2018-11-06 | Ablynx N.V. | Methods for purification of single domain antigen binding molecules |
US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
EP2417162A2 (en) | 2009-04-10 | 2012-02-15 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
CN102388069B (zh) | 2009-04-10 | 2016-01-20 | 埃博灵克斯股份有限公司 | 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽 |
EP2805731B1 (en) * | 2009-09-03 | 2018-10-31 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
WO2011028962A1 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody coformulations |
SI2533761T1 (sl) | 2010-02-11 | 2019-08-30 | Ablynx N.V. | Postopki in sestavki za pripravo aerosolov |
CN110835373A (zh) | 2010-03-01 | 2020-02-25 | 拜耳医药保健有限公司 | 针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体 |
WO2011161263A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Pharmaceutical compositions for cutaneous administration |
AU2011336410B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
KR101875245B1 (ko) | 2010-12-02 | 2018-08-02 | 온콜리틱스 바이오테크 인코포레이티드 | 액체 바이러스 제형 |
CN108329391A (zh) * | 2011-05-27 | 2018-07-27 | 埃博灵克斯股份有限公司 | 使用rankl结合肽抑制骨质吸收 |
JP6178311B2 (ja) * | 2011-07-07 | 2017-08-09 | エルエフビー ユーエスエー インコーポレイテッドLfb Usa, Inc. | タンパク質を安定化する製剤 |
EP2747782B1 (en) | 2011-09-23 | 2018-01-17 | Ablynx NV | Prolonged inhibition of interleukin-6 mediated signaling |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
EP3003369A4 (en) * | 2013-05-28 | 2017-04-26 | Momenta Pharmaceuticals, Inc. | Pharmaceutical compositions comprising pyrophosphate |
EP3209327A1 (en) | 2014-10-21 | 2017-08-30 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
BR112019017853A2 (pt) * | 2017-02-28 | 2021-04-27 | Vib Vzw | Meios e métodos para liberação oral de proteína |
BR112019024333A2 (pt) | 2017-06-02 | 2020-07-28 | Merck Patent Gmbh | imunoglobulinas de ligação adamts |
US11730812B2 (en) * | 2019-03-08 | 2023-08-22 | Boehringer Ingelheim International Gmbh | Anti-IL-36R antibody formulations |
CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2077578B (en) | 1980-01-04 | 1984-05-16 | Marchal Equip Auto | End travel stop gear for motor reducer especially designed for windscreen wipers |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
EP2192131A1 (en) | 1992-08-21 | 2010-06-02 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
CA2258518C (en) | 1996-06-27 | 2011-11-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
CN1203178C (zh) | 1997-10-27 | 2005-05-25 | 尤尼利弗公司 | 多价抗原结合蛋白 |
EP1051493A2 (en) | 1998-01-26 | 2000-11-15 | Unilever Plc | Method for producing antibody fragments |
WO2000040968A1 (en) | 1999-01-05 | 2000-07-13 | Unilever Plc | Binding of antibody fragments to solid supports |
EP1144616B2 (en) | 1999-01-19 | 2009-01-14 | Unilever Plc | Method for producing antibody fragments |
ID30380A (id) | 1999-04-22 | 2001-11-29 | Unilever Nv | Penghambatan infeksi virus menggunakan protein pengikat antigen bervalensi tunggal |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
AU2161501A (en) | 1999-11-29 | 2001-06-25 | Unilever Plc | Immobilized single domain antigen-binding molecules |
ATE342922T1 (de) | 1999-11-29 | 2006-11-15 | Unilever Nv | Immobilisierung von proteinen mit hilfe eines polypeptidsegments |
DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
SE0001916D0 (sv) * | 2000-05-23 | 2000-05-23 | Astrazeneca Ab | Novel formulation |
WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
JP4340062B2 (ja) | 2000-10-12 | 2009-10-07 | ジェネンテック・インコーポレーテッド | 粘度の減少した濃縮タンパク質製剤 |
DK1360207T3 (da) | 2000-12-13 | 2011-09-05 | Bac Ip B V | Proteinarray af variable domæner af tunge immunoglobulinkæder fra kameler |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
ES2338218T3 (es) | 2001-07-25 | 2010-05-05 | Facet Biotech Corporation | Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab. |
EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
PT1441589E (pt) * | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Formulação farmacêutica líquida estável de anticorpos igg |
AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
JP4323317B2 (ja) | 2001-12-21 | 2009-09-02 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 可変領域配列のクローニング方法 |
EP1461085A2 (en) | 2002-01-03 | 2004-09-29 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoconjugates useful for treatment of tumours |
EP2267032A3 (en) | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
KR20080113286A (ko) | 2003-01-10 | 2008-12-29 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자(vWF) 또는 콜라겐에 대한 낙타과로부터의 재조합 VHH 단일 도메인 항체 |
US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
ES2349779T5 (es) | 2003-04-04 | 2013-11-26 | Genentech, Inc. | Formulaciones de anticuerpos y de proteínas a concentración elevada |
AU2003264053A1 (en) | 2003-08-12 | 2005-03-10 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
DE60334645D1 (de) | 2003-11-07 | 2010-12-02 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
ATE473446T1 (de) * | 2005-01-14 | 2010-07-15 | Ablynx Nv | Verfahren und testvorrichtungen zur unterscheidung verschiedener formen von krankheiten und leiden, die durch thrombocytopenia und/oder durch spontane interaktionen zwischen dem von-willebrand-faktor und plättchen gekennzeichnet sind |
WO2006079372A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
PL1888640T3 (pl) | 2005-05-18 | 2012-08-31 | Ablynx Nv | Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa |
KR101414438B1 (ko) | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자에 대한 단일 도메인 vhh 항체 |
DE102005023617A1 (de) | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
EP2322552B1 (en) * | 2005-06-21 | 2016-02-10 | Xoma (Us) Llc | IL-1beta binding antibodies and fragments thereof |
CA2624781A1 (en) | 2005-10-11 | 2007-04-19 | Ablynx N.V. | Nanobodies tm and polypeptides against egfr and igf-ir |
NZ597082A (en) | 2005-10-13 | 2013-11-29 | Human Genome Sciences Inc | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases |
WO2007076062A2 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
SE530085C2 (sv) | 2006-01-30 | 2008-02-26 | Timothy Richard Vinnicombe | Kärl för microvågsugn |
JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン,エルエルシー | タンパク質製剤 |
JP2009529339A (ja) | 2006-03-13 | 2009-08-20 | アブリンクス エン.ヴェー. | Il−6を標的とするアミノ酸配列およびそれを含みil−6介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
KR100817251B1 (ko) | 2006-06-28 | 2008-03-27 | 주식회사 삼정산업 | 철재 파렛트 |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
CA2663042A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
US20100129379A1 (en) | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
AU2007310838A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
CN101631535A (zh) | 2006-12-06 | 2010-01-20 | 惠氏公司 | 含有甘露醇的高蛋白质浓度调配物 |
JP2010512734A (ja) * | 2006-12-13 | 2010-04-30 | アブリンクス エン.ヴェー. | Il−6/il−6受容体複合体等受容体介在性シグナル伝達に関与する複合体に特異的なポリペプチド |
US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
US9156914B2 (en) | 2006-12-19 | 2015-10-13 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
US20100062004A1 (en) | 2006-12-19 | 2010-03-11 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
CN103405768A (zh) * | 2006-12-20 | 2013-11-27 | 爱克索马技术有限公司 | 用于治疗IL-1β相关疾病的方法 |
EP2101801A1 (en) * | 2006-12-20 | 2009-09-23 | Ablynx N.V. | Oral delivery of polypeptides |
US20100166734A1 (en) | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
CA2790018C (en) | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
EP2097451A2 (en) | 2006-12-22 | 2009-09-09 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
CN101663319A (zh) | 2007-02-21 | 2010-03-03 | 埃博灵克斯股份有限公司 | 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病 |
WO2008142165A1 (en) | 2007-05-24 | 2008-11-27 | Ablynx N.V. | Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors |
MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
MX2010005783A (es) | 2007-11-27 | 2010-08-10 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. |
BRPI0907186A2 (pt) | 2008-01-15 | 2015-07-14 | Abbott Gmbh & Co Kg | Composições proteicas pulverizadas e métodos para sua produção |
JP5373823B2 (ja) * | 2008-01-29 | 2013-12-18 | アブリンクス エン.ヴェー. | タンパク質及びポリペプチドを安定化する方法 |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
EP2249801A2 (en) | 2008-02-07 | 2010-11-17 | Amgen Inc. | Stabilized protein compositions |
AU2009221106A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
CN101977654A (zh) * | 2008-03-21 | 2011-02-16 | 埃博灵克斯股份有限公司 | 冯威勒布兰特因子特异性结合物及其应用方法 |
AU2009333791B2 (en) | 2008-10-29 | 2013-04-04 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
KR20110091777A (ko) * | 2008-11-26 | 2011-08-12 | 글락소 그룹 리미티드 | 폴리펩티드, 항체 가변 도메인 및 길항제 |
EP2387583B1 (en) * | 2009-01-14 | 2018-09-19 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
SG10201704214VA (en) * | 2009-01-29 | 2017-06-29 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
US10005830B2 (en) * | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
EP2805731B1 (en) * | 2009-09-03 | 2018-10-31 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
-
2010
- 2010-09-03 EP EP14171120.0A patent/EP2805731B1/en active Active
- 2010-09-03 WO PCT/EP2010/062972 patent/WO2011026945A1/en active Application Filing
- 2010-09-03 EP EP18185772.3A patent/EP3438126B1/en active Active
- 2010-09-03 PL PL10747896T patent/PL2473528T3/pl unknown
- 2010-09-03 EP EP10747895.0A patent/EP2473527B1/en active Active
- 2010-09-03 US US13/393,679 patent/US9884117B2/en active Active
- 2010-09-03 WO PCT/EP2010/062975 patent/WO2011026948A1/en active Application Filing
- 2010-09-03 ES ES10747896T patent/ES2531083T3/es active Active
- 2010-09-03 LT LTEP14171120.0T patent/LT2805731T/lt unknown
- 2010-09-03 PL PL18185772T patent/PL3438126T3/pl unknown
- 2010-09-03 EP EP10747896.8A patent/EP2473528B1/en active Active
- 2010-09-03 SI SI201031846T patent/SI2805731T1/sl unknown
- 2010-09-03 ES ES18185772T patent/ES2831323T3/es active Active
- 2010-09-03 EP EP20176028.7A patent/EP3725330A1/en active Pending
- 2010-09-03 PT PT107478950T patent/PT2473527T/pt unknown
- 2010-09-03 DK DK10747895.0T patent/DK2473527T3/en active
- 2010-09-03 ES ES10747895.0T patent/ES2617180T3/es active Active
- 2010-09-03 PT PT181857723T patent/PT3438126T/pt unknown
- 2010-09-03 US US13/393,636 patent/US20120244158A1/en not_active Abandoned
- 2010-09-03 PT PT10747896T patent/PT2473528E/pt unknown
- 2010-09-03 DK DK10747896T patent/DK2473528T3/en active
-
2015
- 2015-05-22 HK HK15104885.3A patent/HK1204284A1/xx not_active IP Right Cessation
-
2019
- 2019-01-21 HR HRP20190137TT patent/HRP20190137T1/hr unknown
- 2019-01-31 CY CY20191100137T patent/CY1121411T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1121411T1 (el) | 2020-05-29 |
EP2805731A3 (en) | 2015-04-01 |
EP2805731B1 (en) | 2018-10-31 |
PL3438126T3 (pl) | 2021-03-08 |
EP3725330A1 (en) | 2020-10-21 |
WO2011026945A1 (en) | 2011-03-10 |
PL2473528T3 (pl) | 2015-05-29 |
LT2805731T (lt) | 2019-02-11 |
PT2473528E (pt) | 2015-03-04 |
EP2473528A1 (en) | 2012-07-11 |
EP2473527A1 (en) | 2012-07-11 |
DK2473527T3 (en) | 2017-03-06 |
WO2011026948A1 (en) | 2011-03-10 |
PT2473527T (pt) | 2017-02-27 |
PT3438126T (pt) | 2020-11-09 |
EP2473527B1 (en) | 2016-11-30 |
US20120201812A1 (en) | 2012-08-09 |
EP2473528B1 (en) | 2014-12-03 |
ES2617180T3 (es) | 2017-06-15 |
ES2531083T3 (es) | 2015-03-10 |
DK2473528T3 (en) | 2015-03-02 |
US20120244158A1 (en) | 2012-09-27 |
US9884117B2 (en) | 2018-02-06 |
EP2805731A2 (en) | 2014-11-26 |
EP3438126A1 (en) | 2019-02-06 |
EP3438126B1 (en) | 2020-08-19 |
HRP20190137T1 (hr) | 2019-03-22 |
HK1204284A1 (en) | 2015-11-13 |
ES2831323T3 (es) | 2021-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190137T1 (hr) | Stabilne formulacije polipeptida i njihova uporaba | |
HK1250313A1 (zh) | 穩定的藥物組合物和使用所述組合物的方法 | |
IL217280A0 (en) | Compositions comprising combinations of phyto-cannabinoids and uses thereof | |
EP2515946A4 (en) | NANOCONJUGATES AND COMPOSITIONS OF NANOCONJUGATES | |
ZA201300193B (en) | Formulations of rifaximin and uses thereof | |
IL219155A0 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
PT2605757E (pt) | Formulações à base de nalbufina e suas utilizações | |
IL219470A0 (en) | Compositions containing fractalknie-binding proteins and uses thereof | |
HK1172032A1 (en) | Stable sns-595 compositions and methods of preparation sns-595 | |
IL217135A0 (en) | Stabilized herbicidal formulations and methods of use | |
IL219018A (en) | Radzolid Pharmaceuticals and Uses | |
ZA201200260B (en) | Polyphenylsulphone-polytetrafluroethylene compositions and use thereof | |
GB0905790D0 (en) | Novel polypeptides and use thereof | |
EP2508598A4 (en) | PREPARATION OF LIPASE POWDER AND USE THEREOF |